Cardiff Oncology, Inc. (CRDF) Misses Q1 EPS by 1c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q1 EPS of ($0.20), $0.01 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $91.67 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
• Bloom Burton & Co. Upgrades Aurinia Pharmaceuticals (AUPH) to Buy (1)
• Deere shares climb as fiscal Q3 earnings and revenue top estimates